english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Covid-19 and vitamin D: too uncertain

 NEWS UPDATE  Interest has been expressed in using vitamin D in the prevention of Sars-CoV-2 infection or the treatment of covid-19. What evaluation data available as of late 2020 support this hypothesis?
15 December 2020

Fexinidazole (Fexinidazole Winthrop°) and sleeping sickness caused by Trypanosoma brucei gambiense

FEATURED REVIEW Human African trypanosomiasis (or sleeping sickness) is endemic in many countries in sub-Saharan Africa. Is fexinidazole more effective than the standard treatments for sleeping sickness due to T. brucei gambiense? Does it have fewer adverse effects? Is it easier to use?
Full review (5 pages) available for download by subscribers.
1 December 2020

An exemplary initiative

EDITORIALA successful collaboration between the Drugs for Neglected Diseases initiative (DNDi) and several other entities has shown that it is possible to develop drugs that satisfy a genuine need, with the sole aim of providing a therapeutic advance, without the promise of exclusive market access or huge profits.
1 December 2020

In the December issue of Prescrire International: Betibeglogene autotemcel (Zynteglo°) in certain forms of severe beta thalassaemia

FREE DOWNLOAD Despite the uncertainties, an option for achieving transfusion independence in the absence of a compatible donor.
Full text available for free download.
1 December 2020

Updated review of "Drugs to avoid, in the name of better patient care" is published by independent French journal Prescrire

Prescrire "Drugs to avoid" The independent French medical journal Prescrire has published its annual review of "Drugs to avoid", identifying drugs that are clearly more harmful than beneficial. The full report will be published in English in the February 2020 issue of Prescrire International.
1 December 2020

Depression: cardiac risks with citalopram (Seropram° and other brands), even greater if combined with omeprazole (Mopral° and other brands)

Citalopram (Seropram° and other brands), an antidepressant, carries a risk of cardiac rhythm disorders and sudden death, all the more so when combined with omeprazole (Mopral° and other brands), which is often used for gastric reflux and peptic ulcers.
1 December 2020

Drug research: public funding, private profits

Drug companies receive many direct and indirect forms of public aid for pharmaceutical research, but the allocation of this aid lacks transparency, and recipients are not required to market the drugs concerned at affordable prices.
1 December 2020

Mediator°: all wrong from the very start

1 December 2020

Evaluation of covid-19 vaccines: the questions to ask

 NEWS UPDATE  November 2020 has seen a flurry of press releases announcing effective, and apparently relatively safe, vaccines against covid-19. However, as no detailed results have been released, it is impossible to assess the quality and relevance of these claims. When we finally have more than headlines to go on, what questions will need to be asked about these clinical trials? The answers will help determine the usefulness of these vaccines and define the vaccination strategy, taking account of the interests of vaccinees and society as a whole.
20 November 2020

Doxylamine during pregnancy: minimise dose and duration, due to possible link with malformations

FEATURED REVIEW Prescrire's analyses have for many years found doxylamine to be the first-choice antiemetic drug in early pregnancy, when non-pharmacological measures fail. A recent study suggests an increased risk of major birth defects. Does this finding affect doxylamine's harm-benefit balance and its place as the first-choice drug for relieving nausea and vomiting during pregnancy?
Full review (3 pages) available for download by subscribers.
1 November 2020

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90